Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP

Crispr Therapeutics AG (CRSP) Financial Statements

7,949 Followers

Crispr Therapeutics AG Financial Overview

Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-2.721; its P/E ratio is -21.15; Crispr Therapeutics AG is scheduled to report earnings on July 29, 2024, and the estimated EPS forecast is $-1.43. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue$ 504.00K$ 200.00M-$ 70.00M$ 100.00M
Gross Profit$ 504.00K$ 180.00M-$ 70.00M$ 100.00M
EBIT$ -68.90M$ 69.58M$ -111.74M$ -76.82M$ -51.74M
EBITDA$ -64.07M$ 74.48M$ -106.81M$ -71.86M$ -46.69M
Net Income Common Stockholders$ -116.59M$ 89.35M$ -65.31M$ -77.74M$ -53.06M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 2.11B$ 1.69B$ 1.74B$ 1.77B$ 1.88B
Total Assets$ 2.44B$ 2.23B$ 2.09B$ 2.20B$ 2.24B
Total Debt$ 234.93M$ 238.63M$ 241.59M$ 245.18M$ 240.27M
Net Debt$ -1.87B$ -1.46B$ -1.50B$ -1.52B$ -1.64B
Total Liabilities$ 355.08M$ 346.77M$ 359.04M$ 380.99M$ 389.47M
Stockholders Equity$ 2.08B$ 1.88B$ 1.73B$ 1.82B$ 1.85B
Cash Flow-
Free Cash Flow$ 109.03M$ -96.81M$ -41.97M$ -136.80M$ 5.74M
Operating Cash Flow$ 109.75M$ -96.07M$ -39.86M$ -133.25M$ 8.80M
Investing Cash Flow$ -97.80M$ -81.45M$ 121.35M$ 216.92M$ 117.83M
Financing Cash Flow$ 305.93M$ 38.94M$ 1.56M$ 16.77M$ 5.40M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Crispr Therapeutics AG Debt to Assets

Crispr Therapeutics AG Cash Flow

Crispr Therapeutics AG Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis